Open calls · Research grant · Medicine
Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
National Institutes of Health · Aging Research · RFA-NS-28-012
Deadlines
- 10 Oct 2028 Deadline in 699 days
Who can apply
- Where the work is done
- United States
- Who applies
- An organisation
Money
- Per project
- up to $2.5M per project
- Total budget
- $6M
- Expected awards
- 3
About the call
This Notice of Funding Opportunity (NOFO) supports the translation of genome editing and other biologic therapies for Alzheimer's Disease-Related Dementias (ADRD). The program spans the full translational pipeline, from therapeutic lead optimization and drug product development through IND-enabling studies and early clinical evaluation. Supported activities may include optimization of editing constructs and delivery systems; assessment of bioactivity, target engagement, durability, pharmacokinetics, and bioavailability; demonstration of in vivo efficacy; execution of safety pharmacology and toxicology studies; and development of scalable manufacturing processes, formulation strategies, and quality attributes aligned with regulatory expectations.
ADRD include Frontotemporal Dementia (FTD); Lewy Body Dementias (LBD), including Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia (PDD); Vascular Contributions to Cognitive Impairment and Dementia (VCID); and Multiple Etiology Dementias (MED).
Text from the funder (US federal government, public domain).
Conditions in full
Other Eligible ApplicantsEligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
We sort calls into fields, career stages and countries automatically. Always check the conditions on the funder’s page before you apply.
Discussion
Applying too? Looking for partners? Ask here.